{
}
Sandoz, a global leader in generics and biosimilars, is set to confirm its strategic roadmap at the 43rd Annual J.P. Morgan Healthcare Conference, highlighting a robust pipeline of 28 biosimilars and ambitions to lead the US market with three launches expected in 2025. The company reported over 30% sales growth in the first nine months of 2024, driven by its biosimilars, and is strategically positioned to capitalize on a significant market opportunity as reference medicines worth over USD 400 billion lose exclusivity from 2029 onwards.
Sandoz, a global leader in generic and biosimilar medicines, reported over 30% sales growth in the first nine months of 2024, driven by its industry-leading pipeline of 28 biosimilars. The company plans to launch four biosimilars in 2025 and aims to capitalize on a significant market opportunity with over USD 400 billion in reference medicines losing exclusivity from 2029 to 2034. Sandoz is strategically positioned to enhance its market presence, particularly in the US biosimilars sector.
Sandoz, now a standalone company post-Novartis spinoff, is navigating a multi-year transition while achieving significant milestones, including awards for Company of the Year and Leader of the Year. CEO Richard Saynor emphasizes the importance of biosimilars in driving growth, alongside ongoing investments in manufacturing and a commitment to expanding their generics portfolio. With a strong global presence and strategic investments, Sandoz aims to enhance its capabilities and market reach in the evolving pharmaceutical landscape.
Richard Saynor, CEO of Sandoz, emphasizes the need for sustainable drug production amid rising ESG concerns, particularly regarding the environmental impact of packaging waste. He highlights the challenges of domestic drug manufacturing in the West, citing high costs and complex supply chains. With a significant amount of products set to come off patent, Saynor sees vast opportunities in generics, particularly in the wake of the demand for diabetes and weight-loss medications.
Richard Saynor, CEO of Sandoz, aims to position the company as a leader in producing affordable generics and biosimilars, especially as a wave of patents expires. He emphasizes the challenges of sustainable production and the complexities of drug development, while expressing optimism about potential changes in the U.S. healthcare system under the new administration. Saynor believes that making medicines more accessible can significantly expand patient treatment opportunities.
Richard Saynor, CEO of Sandoz Group AG, aims to position the company as a leader in producing generic versions of cutting-edge drugs, including anti-obesity treatments. He highlights the significant market opportunity as many drugs come off patent, but raises concerns about the environmental impact of mass-producing these medications, particularly regarding waste from vials. Saynor emphasizes the need for sustainable solutions in the pharmaceutical industry as demand for these drugs grows.
Sandoz Group AG plans to launch a generic version of Ozempic in Canada by 2026, targeting the growing demand for GLP-1 weight-loss drugs amid high prices for branded options. The company is investing in production to ensure a reliable supply of semaglutide, the active ingredient, as it anticipates significant market potential if prices decrease. With obesity affecting one in three Canadian adults, Sandoz aims to make these effective treatments more accessible.
Sandoz has inaugurated a new Device Development Center in Cambridge, UK, aimed at enhancing the development of drug-device combination products. This state-of-the-art facility will support Sandoz's global pipeline of affordable medicines, leveraging local expertise to accelerate innovation and expand access to generics and biosimilars. The center features advanced engineering and testing labs, reflecting Sandoz's commitment to life sciences innovation and its growth strategy focused on patient access.
Richard Saynor
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Sandoz outlines growth strategy and pipeline at J P Morgan Healthcare Conference
07:30 14.01.2025
sandoz plans four biosimilar launches and reports significant sales growth
United States Dollar
Sandoz Group AG
CHE
Laurent De Weck
Chris Lewis
Richard Saynor
Tamara Hackl
Jörg Allgäuer
Show more
07:00 14.01.2025
sandoz outlines growth strategy and investment plans post novartis spinoff
United States Dollar
Novartis AG
Coherus BioSciences, Inc.
Sandoz Group AG
AUT
SVN
USA
CHE
Richard Saynor
Show more
08:12 23.12.2024
sandoz ceo highlights environmental impact of obesity drugs and market opportunities
10:26 20.12.2024
sandoz ceo highlights challenges and opportunities in obesity drug market
10:00 20.12.2024
sandoz ceo highlights environmental impact of obesity medications in pharma industry
10:00 20.12.2024
sandoz plans generic ozempic launch in canada by 2026
Canadian Dollar
Sandoz Group AG
Eli Lilly & Co
Novo Nordisk A/S
CHN
USA
CAN
Richard Saynor
Show more
13:49 11.12.2024
Sandoz opens advanced device development center in Cambridge to enhance drug delivery
United States Dollar
Sandoz Group AG
GBR
Dave Ahern
Richard Saynor
Claire D'Abreu Hayling
Gillian Merron
Show more
09:00 11.12.2024
Trending
Subcategory
Corporate News
Stock Market Updates
Industry Trends
Industry Mergers & Acquisitions
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Workplace Trends
Retail and Consumer Goods
CEO Changes
Market Analysis and Predictions
Global Trade Developments
Startups & Entrepreneurship
Central Bank Actions
Government Policies
Government Economic Policies
Financial Scams and Security
Domestic Politics
Corporate Social Responsibility
Supply Chain Management
Countries:
Companies:
JPMorgan Chase & Co.
Tesla, Inc.
Barclays PLC
UniCredit S.p.A.
Deutsche Bank Money Market PP
Banco BPM S.p.A.
Credit Suisse Lux Digital Healt
Bank of America Corporation
UBS Group AG
BNP Paribas SA
Apple Inc.
The Goldman Sachs Group, Inc.
Commerzbank AG
CREDIT AGRICOLE
Lloyds Banking Group plc
Wells Fargo & Company
Banco Santander, S.A.
Credit Suisse Strategic Income I
Amazon.com, Inc.
SpaceXCoin USD
Currencies:
United States Dollar
Euro
British Pound Sterling
Swiss Franc
Chinese Yuan
Indian Rupee
Japanese Yen
South Korean Won
Danish Krone
Hong Kong Dollar
Australian Dollar
Offshore Chinese Yuan
Singapore Dollar
Canadian Dollar
Mexican Peso
Norwegian Krone
Indonesian Rupiah
Russian Ruble
Chilean Peso
United Arab Emirates Dirham
People: